GlassScriptPhysician profile
David Washington Glover
NPI 1952323370
$5,690.73
in general payments reported to CMS, 2019-2025
35 companies · $33.98 in 2025
The $33.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $674 · 2021: $966 · 2022: $1,271 · 2023: $1,011 · 2024: $501 · 2025: $33.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.28 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $918.21 | 2021-2024 | |
| Novo Nordisk INC | $660.23 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $566.29 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $457.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $426.02 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $397.07 | 2019-2023 | Verquvo, Belsomra, Vaxelis |
| Amgen INC. | $335.48 | 2019-2023 | Evenity, Prolia |
| Abbott Laboratories | $271.26 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.00 | 2019-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $120.50 | 2020-2024 | Ajovy, Austedo Xr |
| Dexcom, INC. | $116.87 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.76 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $108.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.00 | 2019-2022 | |
| Eisai INC. | $98.71 | 2020-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $90.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.44 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $80.51 | 2020-2023 | |
| Supernus Pharmaceuticals, INC. | $78.84 | 2019-2021 | Tlando, Xyosted |
| E.R. Squibb & Sons, L.L.C. | $70.70 | 2021-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $58.23 | 2019 | |
| Astellas Pharma US INC | $49.73 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.79 | 2019 | |
| Amarin Pharma, INC. | $43.27 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $32.26 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $25.29 | 2021 | |
| Allergan, INC. | $23.28 | 2019 | |
| Sumitomo Pharma America, INC. | $19.13 | 2023 | Gemtesa |
| Agile Therapeutics, INC. | $18.87 | 2021 | |
| Halozyme INC | $16.17 | 2023 | |
| Genentech USA, INC. | $15.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.42 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.01 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $13.76 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.